Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of guselkumab in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Started Jan 2024; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06260163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260163.